Cargando…

Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis

Background: The treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) remains highly debated for its high recurrence and progression risk. This work aimed to verify the efficacy and toxicity of intra-arterial chemotherapy (IAC) plus intravesical chemotherapy (IVC) in high-risk NMIBC. Me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Chunliang, Qiu, Dongxu, Chen, Jinbo, Zu, Xiongbing, Liu, Jinhui, Li, Huihuang, Hu, Jiao, Yi, Zhenglin, He, Tongchen, Chen, Zhi, Cui, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481664/ https://www.ncbi.nlm.nih.gov/pubmed/34603020 http://dx.doi.org/10.3389/fphar.2021.707271

Ejemplares similares

Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: a pooled analysis
por: Qiu, Dongxu, et al.
Publicado: (2020)

Smoking status and pathological response to neoadjuvant chemotherapy among patients with bladder cancer: a pooled analysis
por: He, Tongchen, et al.
Publicado: (2021)

Effects of Fibrin Clot Inhibitors and Statins on the Intravesical Bacille Calmette–Guérin Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis
por: Cai, Zhiyong, et al.
Publicado: (2021)

Adjuvant chemotherapy in patients with locally advanced bladder cancer after neoadjuvant chemotherapy and radical cystectomy: a systematic review and pooled analysis
por: Cai, Zhiyong, et al.
Publicado: (2021)

Recurrence factors in patients with Keratinizing squamous metaplasia of the bladder after surgical management: a single-center retrospective study
por: Yi, Zhenglin, et al.
Publicado: (2021)

Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis
por: Zhang, Chunyu, et al.
Publicado: (2021)

YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy
por: Hu, Jian, et al.
Publicado: (2021)

A novel signature to predict the neoadjuvant chemotherapy response of bladder carcinoma: Results from a territory multicenter real-world study
por: Li, Huihuang, et al.
Publicado: (2022)

RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma
por: Li, Huihuang, et al.
Publicado: (2021)

PMEPA1 Is a Prognostic Biomarker That Correlates With Cell Malignancy and the Tumor Microenvironment in Bladder Cancer
por: Qiu, Dongxu, et al.
Publicado: (2021)

Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma
por: Li, Huihuang, et al.
Publicado: (2022)

Primary mucinous adenocarcinoma of the renal pelvis misdiagnosed as calculous pyonephrosis: a case report and literature review
por: Li, Huihuang, et al.
Publicado: (2020)

A Poliovirus Receptor (CD155)-Related Risk Signature Predicts the Prognosis of Bladder Cancer
por: Luo, Cong, et al.
Publicado: (2021)

Prediction of clinically significant prostate cancer using a novel (68)Ga-PSMA PET-CT and multiparametric MRI-based model
por: Cheng, Chunliang, et al.
Publicado: (2023)

The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study
por: Zhou, Zhongbao, et al.
Publicado: (2021)

miR-616-5p Promotes Invasion and Migration of Bladder Cancer via Downregulating NR2C2 Expression
por: Ren, Wenbiao, et al.
Publicado: (2021)

Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
por: Hu, Jiao, et al.
Publicado: (2021)

A preoperative nomogram predicting the pseudocapsule status in localized renal cell carcinoma
por: Hu, Jiao, et al.
Publicado: (2020)

N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma
por: Guo, Tao, et al.
Publicado: (2021)

BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity
por: Cai, Zhiyong, et al.
Publicado: (2023)

Filling the gaps in the research about second primary malignancies after bladder cancer: Focus on race and histology
por: Othmane, Belaydi, et al.
Publicado: (2022)

5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
por: Hu, Jiao, et al.
Publicado: (2021)

S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8(+) T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
por: Li, Huihuang, et al.
Publicado: (2023)

Molecular vasculogenic mimicry–Related signatures predict clinical outcomes and therapeutic responses in bladder cancer: Results from real-world cohorts
por: Zhang, Chunyu, et al.
Publicado: (2023)

m(6)A-induced lncDBET promotes the malignant progression of bladder cancer through FABP5-mediated lipid metabolism
por: Liu, Peihua, et al.
Publicado: (2022)

Development and validation of a predictive nomogram for the risk of recurrence in patients with cystitis glandularis
por: Hu, Jiao, et al.
Publicado: (2020)

Clinicopathological characteristics and survival outcomes for testicular choriocarcinoma: a population-based study
por: Li, Huihuang, et al.
Publicado: (2021)

N(6)-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target
por: Quan, Chao, et al.
Publicado: (2021)

Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study
por: Hu, Jiao, et al.
Publicado: (2022)

Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer
por: Owusu, Richmond A., et al.
Publicado: (2013)

A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer
por: Ruan, Qiang, et al.
Publicado: (2021)

Safety Assessment of Ultrasound-Assisted Intravesical Chemotherapy in Normal Dogs: A Pilot Study
por: Sasaki, Noboru, et al.
Publicado: (2022)

A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome
por: Chen, Chin-Li, et al.
Publicado: (2021)

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

Ultrasound-assisted intravesical botulinum toxin A delivery attenuates acetic acid—induced bladder hyperactivity in rats
por: Liu, Qinggang, et al.
Publicado: (2023)

Comparison of clinical feasibility and oncological outcomes between video endoscopic and open inguinal lymphadenectomy for penile cancer: A systematic review and meta-analysis
por: Hu, Jiao, et al.
Publicado: (2019)

Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression
por: Delto, Joan C., et al.
Publicado: (2013)

Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome—A Comparative Study of Different Injection Number, Additives and Concentrations
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy
por: Chen, Jinbo, et al.
Publicado: (2016)

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence
por: Zhang, Jianglei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5cbukf1s7nmimd3lsmvufjlcv4